You just read:

CytRx Corporation Highlights Second NantCell Inc. Clinical Trial Evaluating Immuno-Oncology Agents and Cell-based Therapies in Combination with Aldoxorubicin in Patients with Advanced Squamous Cell Carcinoma

News provided by

CytRx Corporation

Feb 05, 2018, 09:00 EST